Waldenström with clinical / biochemical features concerning for transformation to DLBCL:...
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | RF-WM-TRANSFORMATION-PROGRESSION |
|---|---|
| Тип | Тривожна ознака |
| Статус | переглянуто 2026-04-27 | очікує клінічного підпису |
| Хвороби | DIS-WM |
| Джерела | SRC-ESMO-WM-2024 SRC-NCCN-BCELL-2025 |
Походження тривожної ознаки
| Визначення | Waldenström with clinical / biochemical features concerning for transformation to DLBCL: rapid LDH rise, asymmetric / rapidly enlarging nodal or extranodal mass, PET-CT SUVmax >10 (WM rarely PET-avid; high SUV concerning), B-symptoms in previously asymptomatic patient, or hypercalcemia. Mandates urgent excisional biopsy of PET-avid lesion. |
|---|---|
| Клінічний напрям | intensify |
| Категорія | transformation-progression |
Логіка спрацьовування
{
"any_of": [
{
"finding": "ldh_doubled_in_weeks",
"value": true
},
{
"finding": "rapid_progression",
"value": true
},
{
"comparator": ">",
"finding": "pet_suvmax",
"threshold": 10
},
{
"finding": "wm_richter_like_transformation_suspect",
"value": true
},
{
"finding": "biopsy_shows_dlbcl",
"value": true
},
{
"finding": "new_b_symptoms",
"value": true
}
],
"type": "composite_clinical"
}
Нотатки
Histologic transformation to DLBCL occurs in 2-10% WM lifetime (lower than CLL Richter). Once confirmed by biopsy, treat as de novo DLBCL with R-CHOP (with HBV / IgM-flare considerations); MYD88 status of the transformed clone informs prognosis but not initial therapy. Distinct from "IgM flare" — transient IgM rise after rituximab — which is not transformation and resolves spontaneously. PET-CT in baseline WM (rarely indicated for staging) becomes essential when transformation suspected — high SUVmax in single asymmetric lesion mandates excisional biopsy of that lesion (core may miss focal transformation).
Де використовується
Algorithms
ALGO-WM-2L- ALGO-WM-2L